Condition: Advanced Solid Tumor · Sponsor: Latticon Antibody Therapeutics, Inc
This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2 parts: Phase 1 dose-escalation and Phase 2 cohort expansion.
This description comes directly from the study's public registry record.
Lightspeed Study Contact · 202-913-8881 · lightspeed-1@latticon.com
John Li, PhD · john.li@latticon.com
Always discuss trial participation with your own doctor first.
| D&H Cancer Research Center | Margate, Florida, United States | Completed |
| Huntsman Cancer Institute | Salt Lake City, Utah, United States | Terminated |
| Cancer Hospital of Shandong First Medical University | Jinan, Shandong, China | Recruiting |
| The First Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06277219